NCT07087054 2026-03-10
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
Clinical Trials
49 trialsNCT04907643 2026-02-20
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Phase NA Recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT04086485 2025-12-17
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05263050 2025-12-03
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT02270567 2025-11-13
RegisterNET
Wren Laboratories LLC
Enrolling by invitation
NCT05361668 2025-10-31
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT07165132 2025-09-10
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Not yet recruiting
NCT03583528 2025-06-13
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT01398306 2024-05-06
BANN
University Medical Center Groningen
Completed
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00657332 2023-11-28
Clinical and Pathologic Studies in Neuroendocrine Tumors
Stanford University
Withdrawn
NCT05448157 2023-09-22
RGS-GEP-NET
European Institute of Oncology
Unknown
NCT03623984 2023-09-11
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
Phase EARLY_PHASE1 Withdrawn
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT04672876 2021-12-17
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Phase 2 Withdrawn
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT04017104 2021-01-26
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
Unknown
NCT02441062 2020-12-21
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
Phase 2 Completed
NCT01039922 2020-01-23
SwissNET
Insel Gruppe AG, University Hospital Bern
Recruiting
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00688623 2019-01-25
RAMSETE/CDE16
Novartis
Phase 2 Completed
NCT03622333 2018-08-20
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
CHU de Reims
Phase NA Unknown
NCT00227136 2018-04-13
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Western University, Canada
Phase 3 Terminated
NCT01024387 2018-03-08
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02132468 2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2 Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00050349 2017-03-01
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Novartis
Phase 2 Completed
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT01396382 2016-03-29
68Ga
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT02455596 2016-01-05
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2 Unknown
NCT02038738 2014-01-17
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Phase 1/2 Unknown
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00339131 2011-10-12
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.
Phase 1 Completed
NCT00780663 2011-06-15
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Cylene Pharmaceuticals
Phase 2 Completed
NCT01175096 2010-08-04
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital
Phase 1/2 Unknown